FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

William Ebling

Research Profile

Chemicals & Drugs

Concepts & Ideas

Procedures

Phenomena

Physiology

Platelet Activation

Disorders

Co-author Network

Publications

TOP 3
Yu Chen Barrett; William Ebling; Henry J Pieniaszek; Jeffrey T Billheimer; Dietmar Seiffert
Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein IIb/IIIa antagonist.
Joseph Murphy; R Scott Wright; Ihor Gussak; Brent Williams; Robert N Daly; Valerie A Cain; Henry J Pieniaszek; Sherwin K B Sy; William Ebling; Kristen Simonson; Racehl A Wilcox; Stephen L Kopecky
The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease.
Dietmar Seiffert; Andrew M Stern; William Ebling; Richard J Rossi; Yu Chen Barrett; Richard Wynn; Gregory F Hollis; Bokang He; Cathy J Kieras; Donna L Pedicord; Debra Cromley; Tsushung Hua; Robert B Stein; Robert N Daly; Anthony Sferruzza; Henry J Pieniaszek; Jeffrey T Billheimer
Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of William Ebling (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Yu Chen Barrett; William Ebling; Henry J Pieniaszek; Jeffrey T Billheimer; Dietmar Seiffert
Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein IIb/IIIa antagonist.
Journal of pharmaceutical and biomedical analysis 2007;44(4):938-46.
2003: Joseph Murphy; R Scott Wright; Ihor Gussak; Brent Williams; Robert N Daly; Valerie A Cain; Henry J Pieniaszek; Sherwin K B Sy; William Ebling; Kristen Simonson; Racehl A Wilcox; Stephen L Kopecky
The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2003;3(2):101-12.
2003: Dietmar Seiffert; Andrew M Stern; William Ebling; Richard J Rossi; Yu Chen Barrett; Richard Wynn; Gregory F Hollis; Bokang He; Cathy J Kieras; Donna L Pedicord; Debra Cromley; Tsushung Hua; Robert B Stein; Robert N Daly; Anthony Sferruzza; Henry J Pieniaszek; Jeffrey T Billheimer
Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia.
Blood 2003;101(1):58-63.
2002: Michael Fossler; William Ebling; Su Ma; David M Kornhauser; John T Mondick; Jeffrey S Barrett; Dennis Garner; Check Y Quon; Henry J Pieniaszek
Integrated pharmacokinetic/pharmacodynamic model of XV459, a potent and specific GPIIb/IIIa inhibitor, in healthy male volunteers.
Journal of clinical pharmacology 2002;42(12):1326-34.
2002: Henry J Pieniaszek; Sherwin K B Sy; William Ebling; Michael Fossler; Valerie A Cain; John T Mondick; Su Ma; David M Kornhauser
Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
Journal of clinical pharmacology 2002;42(7):738-53.
1999: Jeffrey S Barrett; J Yu; RP Kapil; P Padovani; F Brown; William Ebling; MH Corjay; Thomas M Reilly; Jeffrey M Bozarth; Shaker A Mousa; Henry J Pieniaszek
Disposition and exposure of the fibrinogen receptor antagonist XV459 on alphaIIBbeta3 binding sites in the guinea pig.
Biopharmaceutics & drug disposition 1999;20(6):309-18.